Abstract
Up to 40% of patients with renal cell carcinoma (RCC) with initially localized disease eventually develop metastasis following nephrectomy. The current standard of care for metastatic RCC (mRCC) is targeted therapy. However, complete response remains rare. A state of oligometastatic disease may exist, in which metastases are present in a limited number of locations; such cases may benefit from metastasis-directed local therapy, based on the evidence supporting resection of limited-volume metastases, allowing for improved disease control. We retrospectively analyzed 7 cases of response of RCC metastases, in patients treated with targeted therapies followed by radiation therapy (RT) of residual metastatic lesions in Paoli-Calmettes Institute (Marseille, France). We analyzed disease response rates, response to sequential strategy, relapse at the irradiated locations and disease evolution. The median follow-up was 34.1 months (range, 19.2-54.5 months). No progression at the irradiated sites was observed. A total of 5 patients had stable disease at the irradiated locations at the last follow-up; 3 remained in complete remission at the assessment, and 2 were stable. Excellent local response and clinical benefit may be achieved withou...Continue Reading
References
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerJ Ferrara
Mar 29, 2000·The Journal of Urology·K H TsuiA Belldegrun
Apr 25, 2006·European Urology·Lance WalshYair Lotan
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Jun 6, 2007·Drugs·Bernard Escudier
May 13, 2008·Cancer·Paul RussoMegan A Kagiwada
Apr 3, 2009·BJU International·Danai D DalianiEric Jonasch
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerRobert A Figlin
Jan 6, 2010·Japanese Journal of Clinical Oncology·Yuzuru Niibe, Kazushige Hayakawa
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EscudierUNKNOWN ESMO Guidelines Working Group
Dec 29, 2010·Journal of Radiation Research·Hai-Ping ZhangJie-Jun Wang
Apr 12, 2011·Radiation Oncology·Michelle A StinauerDavid Raben
May 21, 2011·International Journal of Radiation Oncology, Biology, Physics·Michael J ZelefskyYoshiya Yamada
Jun 8, 2011·Cancer·Evan J WuthrickAdam P Dicker
Jan 11, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurence AlbigesBernard Escudier
Oct 5, 2013·Cardiovascular and Interventional Radiology·Olivier PellerinMarc Sapoval
Apr 4, 2014·The Lancet Oncology·Gert De MeerleerMarc Mareel
Citations
Jun 13, 2017·Tumori·Vincenzo FuscoGiuseppe Guglielmi
Oct 28, 2019·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Rémi GrangeGilles Piana
Oct 9, 2019·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·M WespiserA Thiery-Vuillemin